TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00350610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Standard treatment as usual in a community based treatment setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Standard treatment as usual in a community based treatment setting
Study: NCT03262389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose PET CT
Description: Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Acetate C11 PET CT
Description: Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose PET MRI
Description: Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Acetate C11 PET MRI
Description: Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
Study: NCT01073722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of double lumen tube for one-lung ventilation
Description: The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of EZ- Blocker for one-lung ventilation
Description: Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
Study: NCT01995292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enk Fiberoptic Atomizer
Study: NCT01381445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 0.2%
Description: White to slightly coloured opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 2%
Description: White to slightly coloured opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 2%
Description: White to slightly coloured opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: White cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to slightly coloured opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to slightly coloured opaque cream
Study: NCT00547456

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: Oxygen 2-3L Nasal cannula
Study: NCT00289952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: As per standard of care.
Study: NCT00667667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: side alternating vibration device (Board 3000 whole body vibration platform)
Description: 3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: stretching and wellness (control group)
Description: 2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
Study: NCT00350610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for CBT
Description: Standard treatment as usual (TAU) plus computer based therapy using CBT
Study: NCT04350034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xbox training
Description: patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
Study: NCT03556644

Intervention type: RADIATION
Group type: OTHER
Intervention: CTCA imaging
Description: All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
Study: NCT01761682

Intervention type: OTHER
Intervention: Diagnosed as ALL
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Intervention type: OTHER
Intervention: Diagnosed as ALL
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Intervention type: OTHER
Intervention: Diagnosed as ALL
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Study: NCT01905241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomic TSA using RTI
Description: Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Total Shoulder Arthroplasty
Description: Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
Study: NCT00129220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 mg, oral, once daily (evening), for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: 2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral tablets, twice daily (morning and evening), for 3 weeks
Study: NCT04196244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal or body CT with intravenous contrast
Description: Abdominal or body CT with intravenous contrast

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal or body CT without intravenous contrast (native CT)
Description: Abdominal or body CT without intravenous contrast (native CT)
Study: NCT02911324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention Therapy
Description: Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
Study: NCT03270631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FM and MCE
Description: Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.

Intervention type: OTHER
Group type: OTHER
Intervention: FM and sham-MCE
Description: Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: MCE and sham-FM
Description: Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-MCE and sham-FM
Description: Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
Study: NCT03380806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonist
Description: Standard LHRH agonist for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Standard LHRH agonist for 3 years

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Radiation
Description: Pelvic Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiation
Description: Pelvic Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiotherapy (CRT) Prostate Boost
Description: CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
Study: NCT01354834

Intervention type: DRUG
Intervention: hMG
Description: Patients with a condition
Study: NCT03218943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APRV ventilation mode
Description: They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP ventilation moood
Description: start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
Study: NCT00372905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab tiuxetan
Description: Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
Study: NCT03417102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fitusiran
Description: solution for injection; by subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bypassing agents
Description: solution for injection; by intravenous (IV) injection
Study: NCT02663024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: idursulfase beta
Description: IV, weekly infusion for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: idursulfase beta
Description: IV, weekly infusion for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: idursulfase beta
Description: IV, weekly infusion for 24 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: idursulfase
Description: 0.5 mg/kg, iv, weekly infusion for 24 weeks
Study: NCT01990001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enrollment in online reminder system
Description: Study personnel enrolled members in the online reminder system during their office visit.
Study: NCT02500901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
Study: NCT01897090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elimination Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Guidelines for Americans
Study: NCT05096312

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc gluconate
Description: oral zinc gluconate 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]
Description: Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]
Description: Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains cornstarch
Study: NCT01432990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot gait training
Description: Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: Conventional physical therapy program for 60 minute per day for 5 working day per week.
Study: NCT04506801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probalans senior
Description: Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
Study: NCT00868907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 mg risedronate DR tablet
Description: 35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 mg risedronate DR tablet
Description: 35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 35 mg risedronate DR tablet
Description: 35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
Study: NCT02228447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Habits, Healthy Girls Group
Description: The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
Study: NCT04084847

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: berberis vulgaris=barberry
Description: 10 grams of barberry powder will be consumed daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder
Study: NCT03754829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Her Sey Kontrol Altinda (HSKA)
Description: HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Her Sey Kontrol Altinda (HSKA)
Description: HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
Study: NCT04044976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
Study: NCT02033239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
Study: NCT04519580

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: FDG-PET/CT at baseline, week 8 and week 10.
Study: NCT04194073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter calibration population (NightOwl)
Description: The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
Study: NCT02500901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
Study: NCT01833351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Vitamin C
Description: We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Vitamin C
Description: We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Vitamin C
Description: There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Vitamin C
Description: There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.